Logo image of RNA

AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis

NASDAQ:RNA - Nasdaq - US05370A1088 - Common Stock - Currency: USD

33.34  +1.38 (+4.32%)

After market: 33.34 0 (0%)

Fundamental Rating

4

RNA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While RNA has a great health rating, there are worries on its profitability. RNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RNA has reported negative net income.
RNA had a negative operating cash flow in the past year.
RNA had negative earnings in each of the past 5 years.
In the past 5 years RNA reported 4 times negative operating cash flow.
RNA Yearly Net Income VS EBIT VS OCF VS FCFRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of RNA (-17.09%) is better than 80.18% of its industry peers.
Looking at the Return On Equity, with a value of -18.66%, RNA belongs to the top of the industry, outperforming 86.55% of the companies in the same industry.
Industry RankSector Rank
ROA -17.09%
ROE -18.66%
ROIC N/A
ROA(3y)-29.53%
ROA(5y)-25.48%
ROE(3y)-34.47%
ROE(5y)-30.71%
ROIC(3y)N/A
ROIC(5y)N/A
RNA Yearly ROA, ROE, ROICRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNA Yearly Profit, Operating, Gross MarginsRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

8

2. Health

2.1 Basic Checks

RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNA has been increased compared to 1 year ago.
The number of shares outstanding for RNA has been increased compared to 5 years ago.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNA Yearly Shares OutstandingRNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
RNA Yearly Total Debt VS Total AssetsRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

RNA has an Altman-Z score of 17.17. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RNA (17.17) is better than 91.15% of its industry peers.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.17
ROIC/WACCN/A
WACC10.71%
RNA Yearly LT Debt VS Equity VS FCFRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

RNA has a Current Ratio of 17.76. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
RNA's Current ratio of 17.76 is amongst the best of the industry. RNA outperforms 92.92% of its industry peers.
RNA has a Quick Ratio of 17.76. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 17.76, RNA belongs to the best of the industry, outperforming 92.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.76
Quick Ratio 17.76
RNA Yearly Current Assets VS Current LiabilitesRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

RNA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.68%.
The Revenue has decreased by -0.23% in the past year.
The Revenue has been growing by 90.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y12.08%
Revenue growth 5Y90.61%
Sales Q2Q%-17.1%

3.2 Future

The Earnings Per Share is expected to grow by 22.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, RNA will show a very strong growth in Revenue. The Revenue will grow by 113.16% on average per year.
EPS Next Y0.08%
EPS Next 2Y-7.27%
EPS Next 3Y-8.1%
EPS Next 5Y22.11%
Revenue Next Year-55.7%
Revenue Next 2Y-39.75%
Revenue Next 3Y6.81%
Revenue Next 5Y113.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RNA Yearly Revenue VS EstimatesRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
RNA Yearly EPS VS EstimatesRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNA Price Earnings VS Forward Price EarningsRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNA Per share dataRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as RNA's earnings are expected to decrease with -8.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.27%
EPS Next 3Y-8.1%

More info and screens

0

5. Dividend

5.1 Amount

RNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVIDITY BIOSCIENCES INC

NASDAQ:RNA (2/4/2025, 8:05:18 PM)

After market: 33.34 0 (0%)

33.34

+1.38 (+4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners96.66%
Inst Owner Change-0.03%
Ins Owners0.69%
Ins Owner Change9.42%
Market Cap3.98B
Analysts82.67
Price Target69.27 (107.77%)
Short Float %13.68%
Short Ratio12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.1%
Min EPS beat(2)9.54%
Max EPS beat(2)18.66%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-18.51%
Max EPS beat(4)18.66%
EPS beat(8)6
Avg EPS beat(8)6.39%
EPS beat(12)8
Avg EPS beat(12)3.21%
EPS beat(16)10
Avg EPS beat(16)0.25%
Revenue beat(2)0
Avg Revenue beat(2)-34.5%
Min Revenue beat(2)-45.8%
Max Revenue beat(2)-23.21%
Revenue beat(4)1
Avg Revenue beat(4)-28.57%
Min Revenue beat(4)-82.22%
Max Revenue beat(4)36.95%
Revenue beat(8)5
Avg Revenue beat(8)-3.68%
Revenue beat(12)7
Avg Revenue beat(12)-3.62%
Revenue beat(16)11
Avg Revenue beat(16)19.41%
PT rev (1m)-0.53%
PT rev (3m)-0.27%
EPS NQ rev (1m)-5.04%
EPS NQ rev (3m)0.56%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-0.41%
Revenue NQ rev (1m)-36.89%
Revenue NQ rev (3m)-42.17%
Revenue NY rev (1m)2.25%
Revenue NY rev (3m)-23.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 393.18
P/FCF N/A
P/OCF N/A
P/B 2.65
P/tB 2.65
EV/EBITDA N/A
EPS(TTM)-2.88
EYN/A
EPS(NY)-3.34
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0.08
BVpS12.6
TBVpS12.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.09%
ROE -18.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.53%
ROA(5y)-25.48%
ROE(3y)-34.47%
ROE(5y)-30.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.3%
Cap/Sales 39.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.76
Quick Ratio 17.76
Altman-Z 17.17
F-Score4
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)329.5%
Cap/Depr(5y)270.33%
Cap/Sales(3y)38.3%
Cap/Sales(5y)28.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
EPS Next Y0.08%
EPS Next 2Y-7.27%
EPS Next 3Y-8.1%
EPS Next 5Y22.11%
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y12.08%
Revenue growth 5Y90.61%
Sales Q2Q%-17.1%
Revenue Next Year-55.7%
Revenue Next 2Y-39.75%
Revenue Next 3Y6.81%
Revenue Next 5Y113.16%
EBIT growth 1Y-46.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.78%
EBIT Next 3Y-27.01%
EBIT Next 5YN/A
FCF growth 1Y-48.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.64%
OCF growth 3YN/A
OCF growth 5YN/A